Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-25-014185·AN2 Therapeutics, Inc.
Schedule 13G ownership disclosure
AN2 Therapeutics, Inc.
Common Stock, $0.00001 par value per share · CUSIP: 037326105
Event date: 2024-12-31
- Filing-level shares
- 927,201.00
- Percent of class
- 3.1%
- Brii Biosciences Limited
Shares: 927,201.00 · Class: 3.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-014185
- Form type
- SCHEDULE 13G/A
- Filer
- AN2 Therapeutics, Inc.
- CIK
- CIK 1880438
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership